Humacyte Financial Statements From 2010 to 2025

HUMAW Stock  USD 1.58  0.05  3.27%   
Humacyte financial statements provide useful quarterly and yearly information to potential Humacyte investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Humacyte financial statements helps investors assess Humacyte's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Humacyte's valuation are summarized below:
Gross Profit
-77.4 M
Earnings Share
(3.16)
Quarterly Revenue Growth
2.485
There are over one hundred nineteen available fundamental trends for Humacyte, which can be analyzed over time and compared to other ratios. All traders should should confirm Humacyte's regular fundamental trends against the trends from 2010 to 2025 to make sure the company is sustainable. Enterprise Value is likely to climb to about 255.9 M in 2025, whereas Market Cap is likely to drop slightly above 179.5 M in 2025.

Humacyte Total Revenue

0.0

Check Humacyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Humacyte's main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.7 M, Interest Expense of 1.2 M or Selling General Administrative of 21.1 M, as well as many indicators such as Price To Sales Ratio of 96.95, Dividend Yield of 0.0 or PTB Ratio of 20.49. Humacyte financial statements analysis is a perfect complement when working with Humacyte Valuation or Volatility modules.
  
Check out the analysis of Humacyte Correlation against competitors.
For more information on how to buy Humacyte Stock please use our How to Invest in Humacyte guide.

Humacyte Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets196.8 M147.5 M172.3 M
Very volatile
Short and Long Term Debt Total45.8 M66.1 M34.4 M
Slightly volatile
Other Current Liabilities7.8 M10.7 M7.6 M
Pretty Stable
Total Current Liabilities15.7 M21.2 M12.8 M
Slightly volatile
Property Plant And Equipment Net46.6 M40.5 M65.1 M
Slightly volatile
Accounts Payable7.8 M7.5 M3.8 M
Slightly volatile
Cash127.9 M92.5 M102.8 M
Pretty Stable
Non Current Assets Total46.6 M40.5 M65.1 M
Slightly volatile
Cash And Short Term Investments130.1 M92.5 M103.6 M
Pretty Stable
Common Stock Shares Outstanding61.4 M118.9 M40 M
Slightly volatile
Liabilities And Stockholders Equity196.8 M147.5 M172.3 M
Very volatile
Non Current Liabilities Total126.2 M86.6 M77 M
Slightly volatile
Other Current Assets2.9 M3.3 M1.6 M
Slightly volatile
Other Stockholder Equity374.3 M633.5 M187.8 M
Slightly volatile
Total Liabilities137.6 M103.2 M89.3 M
Slightly volatile
Total Current Assets132.7 M95.8 M105.4 M
Slightly volatile
Common Stock10.9 K11.5 K67.5 M
Slightly volatile
Net Tangible Assets74.4 M83.7 M91.3 M
Slightly volatile
Warrants70.4 M79.2 M86.4 M
Slightly volatile
Long Term Debt24 M44.4 M10.2 M
Slightly volatile
Common Stock Total Equity75.3 M84.7 M92.4 M
Slightly volatile
Retained Earnings Total Equity1.1 M1.3 M1.4 M
Slightly volatile
Capital Surpluse2.9 M3.2 M3.5 M
Slightly volatile
Capital Lease Obligations16.9 M17 M23.4 M
Slightly volatile
Long Term Investments80 M90 M98.1 M
Slightly volatile
Property Plant And Equipment Gross52.6 M68.6 M73.7 M
Slightly volatile
Short and Long Term Debt6.1 M9.9 M4.3 M
Slightly volatile
Capital Stock10.9 K11.5 K34 M
Pretty Stable
Non Current Liabilities Other49.5 M44.5 M22.1 M
Slightly volatile
Net Working Capital123.2 M74.6 M59.2 M
Slightly volatile
Short Term Debt5.4 MM4.4 M
Pretty Stable

Humacyte Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization8.7 M8.9 M7.4 M
Slightly volatile
Interest Expense1.2 M1.3 M2.5 M
Very volatile
Selling General Administrative21.1 M26.9 M18.1 M
Slightly volatile
Other Operating Expenses92.9 M115.1 M91.1 M
Very volatile
Research Development72.8 M88 M73.3 M
Pretty Stable
Cost Of Revenue92.4 M88 M64.4 M
Pretty Stable
Total Operating Expenses25.7 M27 M29.3 M
Slightly volatile
Interest Income6.9 M6.6 M1.6 M
Slightly volatile
Reconciled Depreciation6.6 M7.2 M8.1 M
Slightly volatile
Selling And Marketing Expenses2.4 M2.7 M2.9 M
Slightly volatile

Humacyte Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation7.1 M7.9 M5.5 M
Slightly volatile
Begin Period Cash Flow148.4 M172.2 M159.9 M
Slightly volatile
Other Cashflows From Financing Activities61.5 M44.4 M24.8 M
Slightly volatile
Depreciation8.6 M8.9 M7.3 M
Slightly volatile
Capital Expenditures1.9 M2.1 M5.6 M
Slightly volatile
End Period Cash Flow128 M92.9 M102.9 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio96.9512570.5435
Slightly volatile
Days Sales Outstanding7.98.3128.9846
Slightly volatile
Stock Based Compensation To Revenue3.173.562.0636
Slightly volatile
Capex To Depreciation0.370.340.8273
Slightly volatile
EV To Sales53.4666.3840.3069
Slightly volatile
Payables Turnover9.6413.5617.1852
Slightly volatile
Sales General And Administrative To Revenue8.4113.166.3691
Slightly volatile
Research And Ddevelopement To Revenue27.536.3821.9848
Slightly volatile
Capex To Revenue0.650.771.0174
Slightly volatile
Cash Per Share0.850.893.7136
Slightly volatile
Days Payables Outstanding26.4627.85K
Pretty Stable
Income Quality0.570.61.2551
Pretty Stable
Current Ratio10.035.198.7272
Very volatile
Receivables Turnover47.7145.4419.8396
Slightly volatile
Graham Number1.942.0420.4644
Slightly volatile
Capex Per Share0.02410.02540.2594
Slightly volatile
Revenue Per Share0.01660.01750.2057
Slightly volatile
Interest Debt Per Share0.620.651.2542
Slightly volatile
Debt To Assets0.420.40.2164
Slightly volatile
Operating Cycle6.46.7428.6219
Slightly volatile
Days Of Payables Outstanding26.4627.85K
Pretty Stable
Ebt Per Ebit0.791.270.9146
Pretty Stable
Quick Ratio10.035.198.7273
Very volatile
Cash Ratio9.665.028.5228
Very volatile
Days Of Sales Outstanding7.98.3128.9846
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.191.0941
Pretty Stable
Fixed Asset Turnover0.0440.03590.0641
Slightly volatile
Debt Ratio0.420.40.2164
Slightly volatile
Price Sales Ratio96.9512570.5435
Slightly volatile
Asset Turnover0.01730.00880.0267
Slightly volatile

Humacyte Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap179.5 M264.3 M207.3 M
Slightly volatile
Enterprise Value255.9 M243.7 M149.2 M
Slightly volatile

Humacyte Fundamental Market Drivers

Cash And Short Term Investments80.4 M

About Humacyte Financial Statements

Humacyte investors use historical fundamental indicators, such as Humacyte's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Humacyte. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-2.4 M-2.2 M
Cost Of Revenue88 M92.4 M
Stock Based Compensation To Revenue 3.56  3.17 
Sales General And Administrative To Revenue 13.16  8.41 
Research And Ddevelopement To Revenue 36.38  27.50 
Capex To Revenue 0.77  0.65 
Revenue Per Share 0.02  0.02 
Ebit Per Revenue(62.15)(65.26)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Humacyte Stock Analysis

When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.